Charles Schwab Investment Management Inc Bio Atla, Inc. Transaction History

Charles Schwab Investment Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$2.83 - $3.87 $286,155 - $391,315	101,115 Added 548.52%	119,549 $358,000
Q4 2022 Feb 13, 2023	BUY	$6.29 - $11.01 $34,010 - $59,531	5,407 Added 41.51%	18,434 $152,000
Q3 2022 Nov 14, 2022	SELL	$2.94 - $11.87 $224,618 - $906,879	-76,401 Reduced 85.43%	13,027 $101,000
Q2 2022 Aug 15, 2022	SELL	$2.13 - $5.38 $35,398 - $89,410	-16,619 Reduced 15.67%	89,428 $255,000
Q1 2022 May 13, 2022	SELL	$4.38 - $18.78 $54,780 - $234,881	-12,507 Reduced 10.55%	106,047 $531,000
Q4 2021 Feb 11, 2022	BUY	$19.0 - $30.95 $146,642 - $238,872	7,718 Added 6.96%	118,554 $2.33 Million
Q3 2021 Nov 16, 2021	BUY	$29.44 - $43.74 $936,663 - $1.39 Million	31,816 Added 40.26%	110,836 $3.26 Million
Q2 2021 Aug 16, 2021	BUY	$38.07 - $56.17 $104,007 - $153,456	2,732 Added 3.58%	79,020 $3.35 Million
Q1 2021 May 17, 2021	BUY	$32.41 - $70.91 $2.47 Million - $5.41 Million	76,288 New	76,288 $3.88 Million

17.3M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.